TY - JOUR
T1 - Menaquinone-7 supplementation improves arterial stiffness in healthy postmenopausal women A double-blind randomised clinical trial
AU - Knapen, Marjo H. J.
AU - Braam, Lavienja A. J. L. M.
AU - Drummen, Nadja E.
AU - Bekers, Otto
AU - Hoeks, Arnold P. G.
AU - Vermeer, Cees
PY - 2015/5
Y1 - 2015/5
N2 - Observational data suggest a link between menaquinone (MK, vitamin K2) intake and cardiovascular (CV) health. However, MK intervention trials with vascular endpoints are lacking. We investigated long-term effects of MK-7 (180 mu g MenaQ7/day) supplementation on arterial stiffness in a double-blind, placebo-controlled trial. Healthy postmenopausal women (n=244) received either placebo (n=124) or MK-7 (n=120) for three years. Indices of local carotid stiffness (intima: media thickness IMT, Diameter end-diastole and Distension) were measured by echotracking. Regional aortic stiffness (carotid-femoral and carotid-radial Pulse Wave Velocity, cfPWV and crPWV, respectively) was measured using mechanotransducers. Circulating desphospho-uncarboxylated matrix Gla-protein (dp-ucMGP) as well as acute phase markers Interleukin-6 (IL-6), high-sensitive C-reactive protein (hsCRP), tumour necrosis factor-alpha (TNF-alpha) and markers for endothelial dysfunction Vascular Cell Adhesion Molecule (VCAM), E-selectin, and Advanced Glycation Endproducts (AGEs) were measured. At baseline dp-ucMGP was associated with IMT, Diameter, cfPWV and with the mean z-scores of acute phase markers (APMscore) and of markers for endothelial dysfunction (EDFscore). After three year MK-7 supplementation cfPWV and the Stiffness Index beta significantly decreased in the total group, whereas distension, compliance, distensibility,Young's Modulus, and the local carotid PWV (cPWV) improved in women having a baseline Stiffness Index beta above the median of 10.8. MK-7 decreased dp-ucMGP by 50% compared to placebo, but did not influence the markers for acute phase and endothelial dysfunction. In conclusion, long-term use of MK-7 supplements improves arterial stiffness in healthy postmenopausal women, especially in women having a high arterial stiffness.
AB - Observational data suggest a link between menaquinone (MK, vitamin K2) intake and cardiovascular (CV) health. However, MK intervention trials with vascular endpoints are lacking. We investigated long-term effects of MK-7 (180 mu g MenaQ7/day) supplementation on arterial stiffness in a double-blind, placebo-controlled trial. Healthy postmenopausal women (n=244) received either placebo (n=124) or MK-7 (n=120) for three years. Indices of local carotid stiffness (intima: media thickness IMT, Diameter end-diastole and Distension) were measured by echotracking. Regional aortic stiffness (carotid-femoral and carotid-radial Pulse Wave Velocity, cfPWV and crPWV, respectively) was measured using mechanotransducers. Circulating desphospho-uncarboxylated matrix Gla-protein (dp-ucMGP) as well as acute phase markers Interleukin-6 (IL-6), high-sensitive C-reactive protein (hsCRP), tumour necrosis factor-alpha (TNF-alpha) and markers for endothelial dysfunction Vascular Cell Adhesion Molecule (VCAM), E-selectin, and Advanced Glycation Endproducts (AGEs) were measured. At baseline dp-ucMGP was associated with IMT, Diameter, cfPWV and with the mean z-scores of acute phase markers (APMscore) and of markers for endothelial dysfunction (EDFscore). After three year MK-7 supplementation cfPWV and the Stiffness Index beta significantly decreased in the total group, whereas distension, compliance, distensibility,Young's Modulus, and the local carotid PWV (cPWV) improved in women having a baseline Stiffness Index beta above the median of 10.8. MK-7 decreased dp-ucMGP by 50% compared to placebo, but did not influence the markers for acute phase and endothelial dysfunction. In conclusion, long-term use of MK-7 supplements improves arterial stiffness in healthy postmenopausal women, especially in women having a high arterial stiffness.
KW - Arterial stiffness
KW - carotid intima-media thickness
KW - menaquinone-7
KW - pulse wave velocity
KW - Stiffness Index beta
U2 - 10.1160/TH14-08-0675
DO - 10.1160/TH14-08-0675
M3 - Article
C2 - 25694037
SN - 0340-6245
VL - 113
SP - 1135
EP - 1144
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
IS - 5
ER -